The role of PTEN in the progression and survival of prostate cancer
- PMID: 12717346
The role of PTEN in the progression and survival of prostate cancer
Abstract
PTEN (phosphatase and tensin homologue deleted on chromosome-10), a dual specificity phosphatase, is a tumor suppressor gene whose inactivation has been associated with many different types of cancer including prostate cancer. Prostate adenocarcinoma is one of the most commonly diagnosed malignancies afflicting the male population in both the United States and Europe. The frequency of PTEN inactivation appears to increase during the progression of prostatic cancer. The physical loss of the PTEN genetic locus in prostate cancer progression has been well characterized, however the molecular implication of this loss of PTEN remains enigmatic. The purpose of this review is to describe the functional role of PTEN in the molecular pathogenesis of prostatic disease. We review the function of PTEN discussing its association with the phosphoinositol 3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signal transduction pathways. Additionally, we discuss the role of PTEN in the regulation of apoptotic pathways involving the anti-apoptotic gene bcl-2 and the pro-apoptotic ligand TRAIL. We also review the mechanisms that can lead to the loss of PTEN function. We describe genetic inactivation including loss of heterozygosity, haploinsufficiency and mutation. We conclude by outlining epigenetic loss including methylation, post-translational modifications and oxidative stress.
Similar articles
-
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11563-8. doi: 10.1073/pnas.201167798. Epub 2001 Sep 11. Proc Natl Acad Sci U S A. 2001. PMID: 11553783 Free PMC article.
-
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.Mol Endocrinol. 2004 Oct;18(10):2409-23. doi: 10.1210/me.2004-0117. Epub 2004 Jun 17. Mol Endocrinol. 2004. PMID: 15205473
-
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.Cancer Res. 2002 Nov 1;62(21):6141-5. Cancer Res. 2002. PMID: 12414639
-
Pten signaling in gliomas.Neuro Oncol. 2002 Jul;4(3):196-211. Neuro Oncol. 2002. PMID: 12084351 Free PMC article. Review.
-
The biology and clinical relevance of the PTEN tumor suppressor pathway.J Clin Oncol. 2004 Jul 15;22(14):2954-63. doi: 10.1200/JCO.2004.02.141. J Clin Oncol. 2004. PMID: 15254063 Review.
Cited by
-
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells.Int J Biol Sci. 2010 Oct 7;6(6):599-612. doi: 10.7150/ijbs.6.599. Int J Biol Sci. 2010. PMID: 20941378 Free PMC article.
-
CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.Cancer Res. 2014 Apr 1;74(7):2050-61. doi: 10.1158/0008-5472.CAN-13-1659. Epub 2014 Feb 3. Cancer Res. 2014. PMID: 24491799 Free PMC article.
-
BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells.PLoS One. 2013 Sep 5;8(9):e74561. doi: 10.1371/journal.pone.0074561. eCollection 2013. PLoS One. 2013. PMID: 24040284 Free PMC article.
-
PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.Oncogene. 2024 Jan;43(1):22-34. doi: 10.1038/s41388-023-02875-4. Epub 2023 Oct 24. Oncogene. 2024. PMID: 37875657 Free PMC article.
-
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion.Cancer Res. 2011 May 1;71(9):3257-67. doi: 10.1158/0008-5472.CAN-10-2603. Epub 2011 Apr 19. Cancer Res. 2011. PMID: 21505104 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials